What does interventional technologies — net revenues mean?

This metric represents the total net revenue generated from the sale of products and services within the interventional technologies business unit. It reflects the company's market performance in specialized medical devices and procedural solutions designed for surgical or clinical interventions. Tracking this revenue stream provides insight into the adoption rates and competitive positioning of the company's high-growth medical technology portfolio.

Haemonetics (HAE) Interventional Technologies — Net revenues

Screener

Other product segments

Plasma

$155.52M+7.2%

Blood Management Technologies

$88.12M—

Similar metrics at other companies

TFX

TFXInterventional — Net revenues

$211.87M+86.1%

ROP

ROPProduct Revenue — Net revenues

$462.7M+7.7%

TNLDeferred subscription revenue — Net revenues

$42M-2.3%

ROP

ROPTotal Software Revenue — Net revenues

$1.63B+12.4%

TNLDeferred exchange-related revenue — Net revenues

$9M0.0%

GENSubscription and service revenue — Net revenues

$1.28B+26.4%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.8B+4.4%

Enterprise value$4.75B+3.9%

P/E25.3×-10.3×

P/S2.8×+0.1×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	June 28, 2025
Plasma	$155,524	$145,074
Other	35,794	36,662
Apheresis net revenues	$191,318	$181,736
MedSurg
Interventional Technologies	$59,942	$58,483
Blood Management Technologies	88,120	81,175
MedSurg net revenues	$148,062	$139,658
Total net revenues	$339,380	$321,394

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's interventional technologies — net revenues?: Haemonetics (HAE) reported interventional technologies — net revenues of $59.94M in Q2 2026.
What does interventional technologies — net revenues mean?: This metric represents the total net revenue generated from the sale of products and services within the interventional technologies business unit. It reflects the company's market performance in specialized medical devices and procedural solutions designed for surgical or clinical interventions. Tracking this revenue stream provides insight into the adoption rates and competitive positioning of the company's high-growth medical technology portfolio.